Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC

First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).

Related Keywords

New York ,United States ,Austria ,Chile ,Santiago ,Regióetropolitana ,Vienna ,Wien ,Mauricio Burotto ,Benjamina Gartrell ,Manuela Schmidinger ,Bradford Hill Clinical Research Center ,Albert Einstein College Of Medicine ,Rcc Database Consortium ,University Of Vienna ,Genitourinary Cancers Symposium ,New England Journal ,All Endpoints ,Medical University ,Genitourinary Malignancy Program ,Montefiore Einstein Cancer Center ,Albert Einstein College ,Malignant Kidney Neoplasm ,Kidney Cancer ,Renal Cell Cancer ,Renal Cell Carcinoma ,Ancer Kidney ,Ancer Renal Cell ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Biologic Therapy ,Tyrosine Kinase Inhibitor ,Cancer ,Alignant Neoplasia ,Arcinoma ,The ,